

Dated: October 17, 2005.

Robert E. Polson,

Office of the Secretary, Paperwork Reduction Act Reports Clearance Officer.

[FR Doc. 05-21356 Filed 10-25-05; 8:45 am]

BILLING CODE 4168-17-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; Meeting

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Enhancing Utilization of Childhood Immunization Client Recall Practices by Private Providers, RFA; IP 05-088; Improving Vaccination Coverage in the Greater than 65 Years of Age Population, RFA IP 05-091; Influenza Vaccination of Children and Accompanying Adults: Mass Vaccination versus Vaccination in Routine Care, RFA IP 05-094; Effectiveness of a Hospital Based Program for Vaccination of Birth Mothers and Household Contacts with Inactivated Influenza Vaccine, RFA; IP 05-095; and Developing Methods and Strategies to Increase Use of Immunization Registries by Private Providers, RFA IP 05-096.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Enhancing Utilization of Childhood Immunization Client Recall Practices by Private Providers, RFA IP 05-088; Improving Vaccination Coverage in the Greater than 65 Years of Age Population, RFA IP 05-091; Influenza Vaccination of Children and Accompanying Adults: Mass Vaccination versus Vaccination in Routine Care, RFA IP 05-094; Effectiveness of a Hospital Based Program for Vaccination of Birth Mothers and Household Contacts with Inactivated Influenza Vaccine, RFA IP 05-095; and Developing Methods and Strategies to Increase Use of Immunization Registries by Private Providers, RFA IP 05-096.

Times and Dates: 8 a.m.-5 p.m., November 21, 2005 (Closed).

Place: Renaissance Hotel, 1 Hartsfield Center Parkway, Atlanta, GA 30354, Telephone 404.209.9999.

Status: The meeting will be closed to the public in accordance with

provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Enhancing Utilization of Childhood Immunization Client Recall Practices by Private Providers, RFA IP 05-088; Improving Vaccination Coverage in the Greater than 65 Years of Age Population, RFA IP 05-091; Influenza Vaccination of Children and Accompanying Adults: Mass Vaccination versus Vaccination in Routine Care, RFA IP 05-094; Effectiveness of a Hospital Based Program for Vaccination of Birth Mothers and Household Contacts with Inactivated Influenza Vaccine, RFA IP 05-095; and Developing Methods and Strategies to Increase Use of Immunization Registries by Private Providers, RFA IP 05-096.

FOR FURTHER INFORMATION CONTACT: Horace M. Stiles, PHD MPH DDS, Scientific Review Administrator, National Institute for Occupational Safety and Health, CDC, 1600 Clifton Road, NE., MS E-74, Atlanta, GA 30333, Telephone 404-498-2584.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 19, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 05-21341 Filed 10-25-05; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 16, 2005, from 8:30 a.m. to 5:15 p.m. and on November 17, 2005, from 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn Select, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Christine Walsh or Denise Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512391. Please call the Information Line for up-to-date information on this meeting.

Agenda: On November 16, 2005, the committee will hear presentations and discuss the use of Madin-Darby Canine Kidney Cells for manufacture of Inactivated Influenza Vaccines. On November 17, 2005, the committee will discuss developing new Pneumococcal Vaccines for U.S. licensure for adults.

Procedure: On November 16, 2005, from 8:30 a.m. to 5:15 p.m. and on November 17, 2005, from 10 a.m. to 5:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 9, 2005. Oral presentations from the public will be scheduled on November 16, 2005, between approximately 1:45 p.m. and 2:15 p.m. and on November 17, 2005, between approximately 1 p.m. and 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 9, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On November 17, 2005, from 8:30 a.m. to 9:55 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).

Persons attending FDA's advisory committee meetings are advised that the